In contrast, Udovicich et al. observed no differences in the detection rate of PSMA PET/CT between patients with RCC, with and without coexisting sarcomatoid or rhabdoid differentiation of lesions (90.9% vs. 82.0%; p = 0.46), and Tariq et al. also did not note a higher PSMA uptake intensity in metastatic vena cava inferior (IVC) thrombi depending on the presence of adverse patho-morphologic features [55,56]. This evidence concerns the gene FOLH1 and renal cell carcinoma.